Combination therapy of LysGH15 and apigenin as 1new strategy for treating pneumonia caused by Staphylococcus aureus

Applied and Environmental Microbiology

Volumn 82, Issue 1, 2016, Pages 87-94

  Xia, Feifei ^a   Li, Xin ^a   Wang, Bin ^a   Gong, Pengjuan ^a   Xiao, Feng ^a   Yang, Mei ^a   Zhang, Lei ^a   Song, Jun ^a   Hu, Liyuan ^a   Cheng, Mengjun ^a   Sun, Changjiang ^a   Feng, Xin ^a   Lei, Liancheng ^a   Ouyang, Songying ^b   Liu, Zhi Jie ^b   Li, Xinwei ^a   Gu, Jingmin ^a   Hana, Wenyu ^a,c  

^a JILIN UNIVERSITY   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

^c Jiangsu Coinnovation Center for the Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA; ENZYME INHIBITION; MAMMALS; MEDICINE; TISSUE;

ANIMAL EXPERIMENTS; COMBINATION THERAPY; MULTIDRUG RESISTANTS; PROTECTIVE EFFICACY; STAPHYLOCOCCUS AUREUS; THERAPEUTIC POTENTIALS; TRADITIONAL CHINESE MEDICINE; TREATMENT EFFECTS;

FLAVONOIDS;

BACTERIUM; DISEASE TREATMENT; HEALTH STATUS; MEDICINE; PNEUMONIA;

ANIMALIA; BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS; STAPHYLOCOCCUS AUREUS;

ANTIINFECTIVE AGENT; APIGENIN; VIRAL PROTEIN;

ANIMAL; C57BL MOUSE; CHEMISTRY; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; HUMAN; MICROBIOLOGY; MOUSE; PHYSIOLOGY; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGE;

ANIMALS; ANTI-BACTERIAL AGENTS; APIGENIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; PNEUMONIA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES; VIRAL PROTEINS;

EID: 84953896670     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02581-15     Document Type: Article

References (51)

1. Saïd-Salim B, Mathema B, Kreiswirth BN. 2003. Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 24:451-455. http://dx.doi.org/10.1086/502231.
2. Padmanabhan RA, Fraser TG. 2005. The emergence of methicillinresistant Staphylococcus aureus in the community. Cleve Clin J Med 72: 235-241. http://dx.doi.org/10.3949/ccjm.72.3.235.
3. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, Talan DA. 2012. Prevalence of methicillin-resistant Staphylococcus aureus as an etiology of community-acquired pneumonia. Clin Infect Dis 54:1126-1133. http://dx.doi.org/10.1093/cid/cis022.
4. Nguyen HM, Graber CJ. 2010. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 65:24-36. http://dx.doi.org/10.1093/jac/dkp377.
5. Conly JM, Johnston BL. 2003. The emergence of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in Canada. Can J Infect Dis 14:249-251.
6. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. http://dx.doi.org/10.1016/S0140-6736(97)07324-8.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135-136. http://dx.doi.org/10.1093/jac/40.1.135.
8. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. 2003. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302:1569-1571. http://dx.doi.org/10.1126/science.1090956.
9. Fischetti VA. 2011. Exploiting what phage have evolved to control grampositive pathogens. Bacteriophage 1:188-194. http://dx.doi.org/10.4161/bact.1.4.17747.
10. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869.
11. Borysowski J, Weber-Dabrowska B, Gorski A. 2006. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood) 231:366-377.
12. Gu J, Xu W, Lei L, Huang J, Feng X, Sun C, Du C, Zuo J, Li Y, Du T, Li L, Han W. 2011. LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 49:111-117. http://dx.doi.org/10.1128/JCM.01144-10.
13. Gu J, Feng Y, Feng X, Sun C, Lei L, Ding W, Niu F, Jiao L, Yang M, Li Y, Liu X, Song J, Cui Z, Han D, Du C, Yang Y, Ouyang S, Liu ZJ, Han W. 2014. Structural and biochemical characterization reveals LysGH15 as an unprecedented "EF-hand-like" calcium-binding phage lysin. PLoS Pathog 10:e1004109. http://dx.doi.org/10.1371/journal.ppat.1004109.
14. Gu J, Zuo J, Lei L, Zhao H, Sun C, Feng X, Du C, Li X, Yang Y, Han W. 2011. LysGH15 reduces the inflammation caused by lethal methicillinresistant Staphylococcus aureus infection in mice. Bioeng Bugs 2:96-99. http://dx.doi.org/10.4161/bbug.2.2.14883.
15. Henderson B, Poole S, Wilson M. 1996. Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis. Microbiol Rev 60:316-341.
16. Timmerman C, Mattsson E, Martinez-Martinez L, De Graaf L, Van Strijp J, Verbrugh H, Verhoef J, Fleer A. 1993. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 61:4167-4172.
17. Li RW, Lin GD, Myers SP, Leach DN. 2003. Anti-inflammatory activity of Chinese medicinal vine plants. J Ethnopharmacol 85:61-67. http://dx.doi.org/10.1016/S0378-8741(02)00339-2.
18. Schinella G, Tournier H, Prieto J, De Buschiazzo PM, Rios J. 2002. Antioxidant activity of anti-inflammatory plant extracts. Life Sci 70:1023-1033. http://dx.doi.org/10.1016/S0024-3205(01)01482-5.
19. Chen BJ. 2001. Triptolide, a novel immunosuppressive and antiinflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leuk Lymphoma 42:253-265. http://dx.doi.org/10.3109/10428190109064582.
20. Mueller M, Hobiger S, Jungbauer A. 2010. Anti-inflammatory activity of extracts from fruits, herbs and spices. Food Chem 122:987-996. http://dx.doi.org/10.1016/j.foodchem.2010.03.041.
21. Duthie G, Crozier A. 2000. Plant-derived phenolic antioxidants. Curr Opin Lipidol 11:43-47. http://dx.doi.org/10.1097/00041433-200002000-00007.
22. Dong J, Qiu J, Wang J, Li H, Dai X, Zhang Y, Wang X, Tan W, Niu X, Deng X, Zhao S. 2013. Apigenin alleviates the symptoms of Staphylococcus aureus pneumonia by inhibiting the production of alpha-hemolysin. FEMS Microbiol Lett 338:124-131. http://dx.doi.org/10.1111/1574-6968.12040.
23. Li KC, Ho YL, Hsieh WT, Huang SS, Chang YS, Huang GJ. 2015. Apigenin-7-glycoside prevents LPS-induced acute lung injury via downregulation of oxidative enzyme expression and protein activation through inhibition of MAPK phosphorylation. Int J Mol Sci 16:1736-1754. http://dx.doi.org/10.3390/ijms16011736.
24. Xiong YQ, Willard J, Yeaman MR, Cheung AL, Bayer AS. 2006. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J Infect Dis 194:1267-1275. http://dx.doi.org/10.1086/508210.
25. Gouaux E. 1998. α-Hemolysin from Staphylococcus aureus: an archetype of β-barrel, channel-forming toxins. J Struct Biol 121:110-122. http://dx.doi.org/10.1006/jsbi.1998.3959.
26. Ru H, Zhao L, Ding W, Jiao L, Shaw N, Liang W, Zhang L, Hung L-W, Matsugaki N, Wakatsuki S. 2012. S-SAD phasing study of death receptor 6 and its solution conformation revealed by SAXS. Acta CrystallogrDBiol Crystallogr 68:521-530. http://dx.doi.org/10.1107/S0108767312022271,http://dx.doi.org/10.1107/S0907444912004490.
27. Konarev PV, Volkov VV, Sokolova AV, Koch MH, Svergun DI. 2003. PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J Appl Crystallogr 36:1277-1282. http://dx.doi.org/10.1107/S0021889803012779.
28. Svergun D. 1992. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J Appl Crystallogr 25: 495-503. http://dx.doi.org/10.1107/S0021889892001663.
29. Fischer H, de Oliveira Neto M, Napolitano H, Polikarpov I, Craievich A. 2009. Determination of the molecular weight of proteins in solution from a single small-angle X-ray scattering measurement on a relative scale. J Appl Crystallogr 43:101-109. http://dx.doi.org/10.1107/S0021889809043076.
30. Svergun DI, Petoukhov MV, Koch MH. 2001. Determination of domain structure of proteins from X-ray solution scattering. Biophys J 80:2946-2953. http://dx.doi.org/10.1016/S0006-3495(01)76260-1.
31. Worlitzsch D, Kaygin H, Steinhuber A, Dalhoff A, Botzenhart K, Doring G. 2001. Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo. Antimicrob Agents Chemother 45:196-202. http://dx.doi.org/10.1128/AAC.45.1.196-202.2001.
32. Qiu J, Wang D, Xiang H, Feng H, Jiang Y, Xia L, Dong J, Lu J, Yu L, Deng X. 2010. Subinhibitory concentrations of thymol reduce enterotoxins A and B and α-hemolysin production in Staphylococcus aureus isolates. PLoS One 5:e9736. http://dx.doi.org/10.1371/journal.pone.0009736.
33. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685. http://dx.doi.org/10.1038/227680a0.
34. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287-294. http://dx.doi.org/10.1084/jem.20072208.
35. Cui Z, Han D, Sun X, Zhang M, Feng X, Sun C, Gu J, Tong C, Lei L, Han W. 2015. Mannose-modified chitosan microspheres enhance OprFOprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity. Appl Microbiol Biotechnol 99: 667-680. http://dx.doi.org/10.1007/s00253-014-6147-z.
36. Sakamaki F, Ishizaka A, Urano T, Sayama K, Nakamura H, Terashima T, Waki Y, Tasaka S, Hasegawa N, Sato K, Nakagawa N, Obata T, Kanazawa M. 1996. Effect of a specific neutrophil elastase inhibitor, ONO-5046, on endotoxin-induced acute lung injury. Am J Respir Crit Care Med 153:391-397. http://dx.doi.org/10.1164/ajrccm.153.1.8542148.
37. Morimoto K, Amano H, Sonoda F, Baba M, Senba M, Yoshimine H, Yamamoto H, Ii T, Oishi K, Nagatake T. 2001. Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice. Am J Respir Cell Mol Biol 24:608-615. http://dx.doi.org/10.1165/ajrcmb.24.5.4292.
38. Schmeck B, Moog K, Zahlten J, Van Laak V, N'Guessan PD, Opitz B, Rosseau S, Suttorp N, Hippenstiel S. 2006. Streptococcus pneumoniaeinduced c-Jun-N-terminal kinase-and AP-1-dependent IL-8 release by lung epithelial BEAS-2B cells. Respir Res 7:98. http://dx.doi.org/10.1186/1465-9921-7-98.
39. Füssle R, Bhakdi S, Sziegoleit A, Tranum-Jensen J, Kranz T, Wellensiek H-J. 1981. On the mechanism of membrane damage by Staphylococcus aureus alpha-toxin. J Cell Biol 91:83-94. http://dx.doi.org/10.1083/jcb.91.1.83.
40. Koo H, Hayacibara MF, Schobel BD, Cury JA, Rosalen PL, Park YK, Vacca-Smith AM, Bowen WH. 2003. Inhibition of Streptococcus mutans biofilm accumulation and polysaccharide production by apigenin and ttfarnesol. J Antimicrob Chemother 52:782-789. http://dx.doi.org/10.1093/jac/dkg449.
41. Leaver SK, Evans TW. 2007. Acute respiratory distress syndrome. BMJ 335:389-394. http://dx.doi.org/10.1136/bmj.39293.624699.AD.
42. Wyncoll DLA, Evans TW. 1999. Acute respiratory distress syndrome. Lancet 354:497-501. http://dx.doi.org/10.1016/S0140-6736(98)08129-X.
43. Maskrey BH, Megson IL, Whitfield PD, Rossi AG. 2011. Mechanisms of resolution of inflammation: a focus on cardiovascular disease. Arterioscler Thromb Vasc Biol 31:1001-1006. http://dx.doi.org/10.1161/ATVBAHA.110.213850.
44. Ogawa M. 1998. Acute pancreatitis and cytokines: second attack by septic complication leads to organ failure. Pancreas 16:312-315. http://dx.doi.org/10.1097/00006676-199804000-00017.
45. Funakoshi-Tago M, Nakamura K, Tago K, Mashino T, Kasahara T. 2011. Anti-inflammatory activity of structurally related flavonoids, apigenin, luteolin and fisetin. Int Immunopharmacol 11:1150-1159. http://dx.doi.org/10.1016/j.intimp.2011.03.012.
46. Brumfitt W, Hamilton-Miller J. 1989. Methicillin-resistant Staphylococcus aureus. N Engl J Med 320:1188-1196. http://dx.doi.org/10.1056/NEJM198905043201806.
47. Sidjabat H, Nimmo GR, Walsh TR, Binotto E, Htin A, Hayashi Y, Li J, Nation RL, George N, Paterson DL. 2011. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-β-lactamase. Clin Infect Dis 52:481-484. http://dx.doi.org/10.1093/cid/ciq178.
48. Hermoso JA, Garcia JL, Garcia P. 2007. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 10:461-472. http://dx.doi.org/10.1016/j.mib.2007.08.002.
49. Rasko DA, Sperandio V. 2010. Antivirulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9:117-128. http://dx.doi.org/10.1038/nrd3013.
50. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603-1612. http://dx.doi.org/10.1128/AAC.01625-09.
51. Yang ZC, Wang BC, Yang XS, Wang Q, Ran L. 2005. The synergistic activity of antibiotics combined with eight traditional Chinese medicines against two different strains of Staphylococcus aureus. Colloids Surf B Biointerfaces 41:79-81. http://dx.doi.org/10.1016/j.colsurfb.2004.10.033.